Adjuvant Chemotherapy for Endometrial Cancer (ACE) trial: A randomized phase II study for advanced endometrial carcinoma

This study evaluated the feasibility and efficacy of three postoperative adjuvant chemotherapy regimens for endometrial cancer. Endometrioid cancer patients with intermediate‐risk stage I and II or high‐risk stage III and IV disease were randomly assigned to receive six cycles of either paclitaxel‐epirubicin‐carboplatin (TEC), paclitaxel‐anthracycline (doxorubicin)‐carboplatin (TAC), or dose‐dense paclitaxel‐carboplatin (ddTC). The primary end‐point was the completion rate (CRate) of six cycles of treatment. The secondary end‐points were progression‐free survival (PFS) and overall survival (OS). One hundred and one patients were treated as follows: 33 received TEC, 33 TAC, and 35 ddTC. The CRates for TEC, TAC, and ddTC were 94%, 64%, and 69%, respectively (P = .005). The TEC CRate was significantly higher than for the other two groups. However, the PFS and OS outcomes were not statistically different between the three groups. The 2‐year survival rates were 94%, 97%, and 97% for TEC, TAC, and ddTC, respectively. When compared to the current standard treatments for endometrial cancer, TEC is a promising candidate for a phase III trial based on its significantly superior CRate and equivalent PFS and OS. This study is registered with UMIN Clinical Trials Registry (UMIN000008911).

[1]  T. Bosse,et al.  Adjuvant therapy for endometrial cancer in the era of molecular classification: radiotherapy, chemoradiation and novel targets for therapy , 2020, International Journal of Gynecological Cancer.

[2]  D. Cella,et al.  Carboplatin and Paclitaxel for Advanced Endometrial Cancer: Final Overall Survival and Adverse Event Analysis of a Phase III Trial (NRG Oncology/GOG0209). , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  W. E. Richards,et al.  Adjuvant Chemotherapy plus Radiation for Locally Advanced Endometrial Cancer. , 2019, The New England journal of medicine.

[4]  K. Ushijima,et al.  Effect of Taxane Plus Platinum Regimens vs Doxorubicin Plus Cisplatin as Adjuvant Chemotherapy for Endometrial Cancer at a High Risk of Progression: A Randomized Clinical Trial. , 2019, JAMA oncology.

[5]  H. Putter,et al.  Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial , 2018, The Lancet. Oncology.

[6]  A. Yasmeen,et al.  Dose dense carboplatin paclitaxel improves progression free survival in patients with endometrial cancer. , 2017, Gynecologic oncology.

[7]  H. Katabuchi,et al.  Assessing the effect of guideline introduction on clinical practice and outcome in patients with endometrial cancer in Japan: a project of the Japan Society of Gynecologic Oncology (JSGO) guideline evaluation committee , 2017, Journal of gynecologic oncology.

[8]  G. Fleming,et al.  Chemotherapy for Endometrial Cancer in Adjuvant and Advanced Disease Settings. , 2016, The oncologist.

[9]  J. Ledermann,et al.  ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer , 2015, International Journal of Gynecologic Cancer.

[10]  D. Katsaros,et al.  Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial. , 2014, The Lancet. Oncology.

[11]  T. Enomoto,et al.  Investigating the relative efficacies of combination chemotherapy of paclitaxel/carboplatin, with or without anthracycline, for endometrial carcinoma , 2011, Archives of Gynecology and Obstetrics.

[12]  T. Enomoto,et al.  Chemotherapy for endometrial carcinoma (GOGO-EM1 study): TEC (paclitaxel, epirubicin, and carboplatin) is an effective remission-induction and adjuvant therapy , 2011, Cancer Chemotherapy and Pharmacology.

[13]  R. Coleman,et al.  A feasibility study of carboplatin and weekly paclitaxel combination chemotherapy in endometrial cancer: a Kansai Clinical Oncology Group study (KCOG0015 trial). , 2011, Gynecologic oncology.

[14]  P. Zola,et al.  Sequential adjuvant chemotherapy and radiotherapy in endometrial cancer--results from two randomised studies. , 2010, European journal of cancer.

[15]  T. Jobo,et al.  Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial , 2009, The Lancet.

[16]  M. Dimopoulos,et al.  Paclitaxel, epirubicin, and carboplatin in advanced or recurrent endometrial carcinoma: a Hellenic Co-operative Oncology Group (HeCOG) study. , 2008, Gynecologic Oncology.

[17]  P. Zola,et al.  Adjuvant chemotherapy vs radiotherapy in high-risk endometrial carcinoma: results of a randomised trial , 2006, British Journal of Cancer.

[18]  R. Barakat,et al.  Paclitaxel and carboplatin in the treatment of advanced or recurrent endometrial cancer: a large retrospective study , 2006, International Journal of Gynecologic Cancer.

[19]  R. Burger,et al.  Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  D J Sargent,et al.  A flexible design for multiple armed screening trials , 2001, Statistics in medicine.